Immune checkpoint blockade is less efficient in patients bearing immunologically 'cold' tumors. Oncolytic viruses, which were originally discovered for their ability to preferentially kill malignant cells, can recondition the tumor microenvironment. Supporting this hypothesis, two new studies published in show that adjuvant-like activities of oncolytic viruses make brain and breast tumors 'hot' and sensitize them for subsequent immune checkpoint blockade.